Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Global 100 Large-Caps (ex-AUS)

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

Classic Minerals Ltd

CLZ

Classic Minerals Ltd. engages in exploration of mineral resource-based projects, focusing on gold and nickel. The company is headquartered in Perth, Western Australia. The company went IPO on 2013-05-24. The firm holds approximately 578 square kilometers of tenements across two regional exploration areas in minerals-rich West Australia. The company is focused on gold deposits in Western Australia's Goldfields region at Forrestania and Kat Gap. Its flagship Kat Gap Gold Project is located approximately 170 kilometers (km) south of Southern Cross and also 50 km south of the Company's Forrestania Gold Project. The Forrestania Gold Project is located approximately 120 km south of Southern Cross, Western Australia and contains the Lady Ada and Lady Magdalene deposits. Its Fraser Range Project (E28/1904) is approximately 40 km to the northeast of Sirius Nova deposit on the Fraser-Albany Mobile Belt, approximately 160 km east southeast of Kambalda and is of interpreted Proterozoic age. The company holds approximately 28 km of strike across 84 square kilometers.

Imugene

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Vanguard Diversified High Growth Funds

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.